NasdaqGM - Nasdaq Real Time Price USD

PureTech Health plc (PRTC)

16.78

+0.01

+(0.06%)

At close: May 9 at 4:00:00 PM EDT

16.85

+0.07

+(0.41%)

After hours: May 9 at 4:05:12 PM EDT

PureTech Announces Publication of New Research Highlighting Untold Experiences of People Living with Idiopathic Pulmonary Fibrosis (IPF)

BOSTON, May 09, 2025--PureTech Announces Publication of New Research Highlighting Untold Experiences of People Living with Idiopathic Pulmonary Fibrosis (IPF)

Business Wire yesterday

PRTC
+0.06%

PTCHF
Shareholders In PureTech Health (LON:PRTC) Should Look Beyond Earnings For The Full Story

Even though PureTech Health plc ( LON:PRTC ) posted strong earnings recently, the stock hasn't reacted in a large way...

Simply Wall St. 4 days ago

PRTC
+0.06%

PTCHF
PureTech Health PLC (PTCHF) (FY 2024) Earnings Call Highlights: Strong Financial Execution and ...

PureTech Health PLC (PTCHF) reports robust cash position, successful clinical trials, and strategic monetization, despite market valuation challenges.

GuruFocus.com 8 days ago

PRTC
+0.06%
PureTech to Present Results from Phase 2b ELEVATE IPF Trial of Deupirfenidone (LYT-100) at the American Thoracic Society International Conference

BOSTON, May 01, 2025--PureTech to Present Results from Phase 2b ELEVATE IPF Trial of Deupirfenidone (LYT-100) at the American Thoracic Society International Conference

Business Wire 9 days ago

PRTC
+0.06%

PTCHF
PureTech Announces Annual Results for Year Ended December 31, 2024

BOSTON, April 30, 2025--PureTech Announces Annual Results for Year Ended December 31, 2024

Business Wire 11 days ago

PRTC
+0.06%

PTCHF
PureTech Health: Notice of Results

BOSTON, April 23, 2025--PureTech Health: Notice of Results

Business Wire 18 days ago

PRTC
+0.06%

PTCHF
PureTech Appoints Peel Hunt as Joint UK Corporate Broker

BOSTON, April 09, 2025--PureTech Appoints Peel Hunt as Joint UK Corporate Broker

Business Wire last month

PRTC
+0.06%

PTCHF
PureTech Health plc Statement Regarding Press Speculation

BOSTON, April 07, 2025--Statement regarding press speculation

Business Wire last month

PRTC
+0.06%

PTCHF
PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

BOSTON, March 11, 2025--PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

Business Wire last month

PRTC
+0.06%

PTCHF
PureTech to Present at the Leerink Partners Global Healthcare Conference

BOSTON, February 25, 2025--PureTech to Present at the Leerink Partners Global Healthcare Conference

Business Wire 2 months ago

PRTC
+0.06%

PTCHF
PureTech Founded Entity Seaport Therapeutics Announces the Publication of New Research Demonstrating Increased Lymphatic Transport with up to 55 Percent Drug Absorption via Lymphatics with GlyphTM Platform

BOSTON, February 12, 2025--PureTech Founded Entity Seaport Therapeutics Announces Publication of New Research Demonstrating Increased Lymphatic Transport with Glyph Platform

Business Wire 2 months ago

PRTC
+0.06%

PTCHF
PureTech Founded Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine

BOSTON, January 27, 2025--PureTech Founded Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine

Business Wire 3 months ago

PRTC
+0.06%

PTCHF
PureTech announces receipt of FDA Fast Track Designation for LYT-200 in AML

PureTech Health (PRTC) announced that the U.S. Food and Drug Administration has granted Fast Track designation to LYT-200, a first-in-class anti-galectin-9 monoclonal antibody, for the treatment of acute myeloid leukemia. “Fast Track designation is a process designed to streamline the development and accelerate the assessment of drugs that target serious conditions with unmet medical need,” the company stated. The FDA has also granted orphan drug designation to LYT-200 for the treatment of AML a

TipRanks 3 months ago

PRTC
+0.06%

PTCHF
PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML)

BOSTON, January 09, 2025--PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML)

Business Wire 3 months ago

PRTC
+0.06%

PTCHF
PureTech to Present at 43rd Annual J.P. Morgan Healthcare Conference

BOSTON, January 08, 2025--PureTech to present at 43rd annual J.P. Morgan Healthcare Conference.

Business Wire 3 months ago

PRTC
+0.06%

PTCHF
PureTech Appoints UBS as UK Corporate Broker

BOSTON, January 06, 2025--PureTech Appoints UBS as UK Corporate Broker.

Business Wire 4 months ago

PRTC
+0.06%

PTCHF
PureTech's Lung Disease Candidate Slowed Lung Function Decline In Idiopathic Pulmonary Fibrosis Patients

PureTech Health plc (NASDAQ:PRTC) stock is up on Monday, after the company announced results from ELEVATE IPF Phase 2b trial of deupirfenidone (LYT-100) for idiopathic pulmonary fibrosis (IPF). The trial evaluated deupirfenidone at two doses three times a day (TID) over 26 weeks in IPF patients. Participants in the trial were randomized 1:1:1:1 to receive deupirfenidone 550 mg, deupirfenidone 825 mg, pirfenidone 801 mg (the FDA-approved dose), or placebo TID for 26 weeks, and had the option to e

Benzinga 4 months ago

PRTC
+0.06%
PureTech’s Deupirfenidone (LYT-100) Slowed Lung Function Decline in People with Idiopathic Pulmonary Fibrosis (IPF) as Measured by Forced Vital Capacity (FVC), Achieving the Primary and Key Secondary Endpoints in the ELEVATE IPF Phase 2b Trial

BOSTON, December 16, 2024--PureTech’s Deupirfenidone Slowed Lung Function Decline in People w/ IPF, Achieving the Primary & Key Secondary Endpoints in ELEVATE IPF Phase 2b Trial

Business Wire 4 months ago

PRTC
+0.06%

PTCHF
With 71% institutional ownership, PureTech Health plc (LON:PRTC) is a favorite amongst the big guns

Key Insights Institutions' substantial holdings in PureTech Health implies that they have significant influence over...

Simply Wall St. 4 months ago

PRTC
+0.06%

PTCHF
PureTech Founded Entity Seaport Therapeutics Presents Additional Data from Phase 1 Study of SPT-300 at ACNP Annual Meeting 2024

BOSTON, December 11, 2024--PureTech Founded Entity Seaport Therapeutics Presents Additional Data from Phase 1 Study of SPT-300 at ACNP Annual Meeting 2024

Business Wire 4 months ago

PRTC
+0.06%

PTCHF

Performance Overview

Return	PRTC	FTSE 100 (^FTSE)
YTD	-11.59%	+4.67%
1-Year	-38.89%	+2.07%
3-Year	-21.91%	+18.54%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

PureTech Health plc (PRTC)

PureTech Announces Publication of New Research Highlighting Untold Experiences of People Living with Idiopathic Pulmonary Fibrosis (IPF)

Shareholders In PureTech Health (LON:PRTC) Should Look Beyond Earnings For The Full Story

PureTech Health PLC (PTCHF) (FY 2024) Earnings Call Highlights: Strong Financial Execution and ...

PureTech to Present Results from Phase 2b ELEVATE IPF Trial of Deupirfenidone (LYT-100) at the American Thoracic Society International Conference

PureTech Announces Annual Results for Year Ended December 31, 2024

PureTech Health: Notice of Results

PureTech Appoints Peel Hunt as Joint UK Corporate Broker

PureTech Health plc Statement Regarding Press Speculation

PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

PureTech to Present at the Leerink Partners Global Healthcare Conference

PureTech Founded Entity Seaport Therapeutics Announces the Publication of New Research Demonstrating Increased Lymphatic Transport with up to 55 Percent Drug Absorption via Lymphatics with GlyphTM Platform

PureTech Founded Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine

PureTech announces receipt of FDA Fast Track Designation for LYT-200 in AML

PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML)

PureTech to Present at 43rd Annual J.P. Morgan Healthcare Conference

PureTech Appoints UBS as UK Corporate Broker

PureTech's Lung Disease Candidate Slowed Lung Function Decline In Idiopathic Pulmonary Fibrosis Patients

PureTech’s Deupirfenidone (LYT-100) Slowed Lung Function Decline in People with Idiopathic Pulmonary Fibrosis (IPF) as Measured by Forced Vital Capacity (FVC), Achieving the Primary and Key Secondary Endpoints in the ELEVATE IPF Phase 2b Trial

With 71% institutional ownership, PureTech Health plc (LON:PRTC) is a favorite amongst the big guns

PureTech Founded Entity Seaport Therapeutics Presents Additional Data from Phase 1 Study of SPT-300 at ACNP Annual Meeting 2024

Performance Overview